Revenue Breakdown
Composition ()
No data
Revenue Streams
West Pharmaceutical Services Inc (WST) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is High Value Components, accounting for 48.0% of total sales, equivalent to $386.21M. Other significant revenue streams include Contract-Manufactured Products and Standard Packaging. Understanding this composition is critical for investors evaluating how WST navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, West Pharmaceutical Services Inc maintains a gross margin of 36.58%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 21.85%, while the net margin is 17.40%. These profitability ratios, combined with a Return on Equity (ROE) of 16.94%, provide a clear picture of how effectively WST converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, WST competes directly with industry leaders such as ZBH and HOLX. With a market capitalization of $16.44B, it holds a significant position in the sector. When comparing efficiency, WST's gross margin of 36.58% stands against ZBH's 63.24% and HOLX's 55.75%. Such benchmarking helps identify whether West Pharmaceutical Services Inc is trading at a premium or discount relative to its financial performance.
